Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (80)	9/13/2006 9:53:45 AM
From: dr.praveen	Read Replies (1) \| Respond to of 285

Hi Ian & Elisabeth, I listened to the c/c. My msg 78 is after the c/c. Though the no's are small in the P2A with 300mg dose, the efficacy signal is strong with 61%. I don't worry about the p value at this stage, still it is significant at p=0.048. They are going to analyse the full PK/PD data from the current studies and start a P2B trial early 07. Ideally they should have had a 150mg dose too with the 300 and 600 in P2A. However from now on, Cardiome should be designing their trials very carefully. The lower the dose, the better with the best possible efficacy coz the drug will be taken for a long duration. No significant SE with the 600mg dose which is good. Regards, Praveen